Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The selection of antipsychotic in early stages of the illness is mainly determined by its
clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug
treatment for individuals suffering from schizophrenia. It is clear that SGAs are not a
homogeneous group and clinical effects and profile of side effects differ between SGAs.
Differences among antipsychotics in terms of effectiveness have turned out to be a topic of
increasing research interest, although comparisons between the different SGAs are scarce. In
first episode of psychosis, SGAs have shown a higher treatment effectiveness compared to
first generation antipsychotics (FGAs) (findings primarily driven by Haloperidol). Less
evident seems to be the notion that some of the SGAs might be more effective (in terms of
treatment discontinuation) than others. Most of the medium-term randomized studies have shown
similar rates of all-cause treatment discontinuation in first episode patients treated with
different SGAs. It may be concluded that more randomized controlled trails should be
accomplished to determine the position of frequently used SGAs in clinical practice. The
investigators undertook this study with the major objective of comparing the clinical
effectiveness of three widely utilized SGAs (Aripiprazole, Ziprasidone and Quetiapine) in the
acute treatment of first-episode non-affective psychosis individuals.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Marques de Valdecilla
Collaborators:
Centro de Investigación Biomédica en Red de Salud Mental Instituto de Investigación Marqués de Valdecilla